

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number
WO 2005/097058 A3

(51) International Patent Classification:

A61K 47/48 (2006.01) A61K 31/198 (2006.01)
A61K 31/515 (2006.01) A61K 47/18 (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:

PCT/EP2005/003348

(22) International Filing Date: 31 March 2005 (31.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

04007921.2 1 April 2004 (01.04.2004) EP

(71) Applicants (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstr.124, CH-4070 Basel (CH). **UNIVERSITE DE LIEGE** [BE/BE]; Quai Van Beneden, 25, B-4020 Liège (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARTSCH, Pierre** [BE/BE]; Av. E. Digneffe, 60, B-4000 Liège (BE). **CATALDO, Didier** [BE/BE]; Rue Vaux, 363, B-4870

Trooz (BE). **ENDELE, Richard** [DE/DE]; Richard-Wagner-Strasse 39b, 69259 Wilhelmsfeld (DE). **EVARD, Brigitte** [BE/BE]; Grand Route, 94, B-4537 Verlaine (BE). **FOIDART, Jean-Michel** [BE/BE]; 3, rue sur la Heid, B-4870 Trooz (BE). **KRELL, Hans-Willi** [AT/DE]; Zugspitzstrasse 14a, 82377 Penzberg (DE). **ZIMMERMANN Gerd** [DE/DE]; Rheinstrasse 9, 76351 Linkenheim (DE).


(74) Agents: **SCHREINER, Siegfried** et al.; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 1152, 82372 Penzberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: CYCLODEXTRIN INCLUSIONS COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES



(57) Abstract: It was surprisingly found that a-trioxypyrimidine-cyclodextrin-complex formed of a trioxypyrimidine derivative represented by the below-described formula (I) and a water-soluble cyclodextrin (further abbreviated as CD) exhibits enhanced water solubility, excellent stability, and low topical stimulation and is useful as a therapeutic agent. Accordingly, the present invention provides a trioxypyrimidine-cyclodextrin complex formed of a trioxypyrimidine derivative or a salt thereof and a cyclodextrin, preferably α -, β - or γ -cyclodextrin or a water-soluble cyclodextrin derivative (water-soluble being defined as a solubility of at least 0.5 gr/100ml water at 25°C), wherein the trioxypyrimidine derivative is represented by formula (I). It was furthermore found that such a trioxypyrimidine complex with cyclodextrin and an adjuvant such as L-lysine or L-arginine show improved water solubility and bioavailability, excellent stability, and low topical stimulation and is useful as a therapeutic agent.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*

(88) Date of publication of the international search report:

17 August 2006

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*